Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 19Gastrointestinal 12Genitourinary 11Lymphoid 10Head & Neck 9CNS 9Thoracic 8Gynecologic 8Sarcoma 5Endocrine 5Plasma cell 4Other solid neoplasm 4Other hematologic neoplasm 4NET 4Tumor-Agnostic 3Dermatologic 3

Conditions

Multiple Myeloma 3Leukemia, Plasma Cell 1

Interventions

Dexamethasone 262Lenalidomide 157daratumumab 135Bortezomib 113pomalidomide 89Calcium Dobesilate 86Cyclophosphamide 84carfilzomib 76Specimen Handling 46isatuximab 44fludarabine 43Biopsy 43belantamab mafodotin 41Magnetic Resonance Spectroscopy 38dexamethasone acetate 34dexamethasone 21-phosphate 34auricularum 33Melphalan 32talquetamab 29ixazomib 27iberdomide 27fludarabine phosphate 24selinexor 22elotuzumab 21Whole-Body Irradiation 17X-Rays 15venetoclax 14Mycophenolic Acid 13tocilizumab 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Fluorodeoxyglucose F18 × Plasma cell × 1 year × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT07463807 2026-05-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
162 enrolled
Plasma cell

Multiple Myeloma

NCT06385652 2026-04-16

PET Imaging Study of 68Ga-NB381 in Multiple Myeloma

Peking University First Hospital

Phase EARLY_PHASE1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT05892393 2025-11-12

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

University of California, San Francisco

Phase 1 Recruiting
20 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡